Abstract
Background: Lung injury and STAT1 deficit induce EGFR overexpression in SARS-CoV-2 infection. Patients & methods: A phase I/II trial was done to evaluate the safety and preliminary effect of nimotuzumab, an anti-EGFR antibody, in COVID-19 patients. Patients received from one to three infusions together with other drugs included in the national guideline. Results: 41 patients (31 severe and 10 moderate) received nimotuzumab. The median age was 62 years and the main comorbidities were hypertension, diabetes and cardiovascular disease. The antibody was very safe and the 14-day recovery rate was 82.9%. Inflammatory markers decreased over time. Patients did not show signs of fibrosis. Conclusion: Nimotuzumab is a safe antibody that might reduce inflammation and prevent fibrosis in severe and moderate COVID-19 patients. Clinical Trial Registration: RPCEC00000369 (rpcec.sld.cu).
Keywords: COVID-19; EGFR; SARS-CoV-2; fibrosis; inflammation; monoclonal antibody; nimotuzumab.
【저자키워드】 COVID-19, SARS-CoV-2, Inflammation, monoclonal antibody, fibrosis, EGFR, nimotuzumab., 【초록키워드】 Trial, antibody, SARS-COV-2 infection, Comorbidity, cardiovascular disease, drug, hypertension, Moderate COVID-19, clinical, Patient, Stat1, moderate, patients, COVID-19 patients, monoclonal, marker, Injury, Safe, median age, National, overexpression, Prevent, evaluate, induce, reduce, diabete, was done, 【제목키워드】 Treatment, blocking,